Search for a trial

Randomized, double-blind (for clazosentan), placebo- and moxifloxacin-controlled, 3-way cross-over Phase 1 study to assess the effect of two intravenous doses of clazosentan on the QTc interval duration in healthy subjects

This study aims at investigating potential relevant QT effects of clazosentan at supra therapeutic doses in healthy male and female subjects using a concentration/response analysis approach in compliance with the ICH E14 guidance [FDA 2017].Primary…